Clinical Trials
9 trialsNCT01412515 2026-06-04
A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma
Institut National de la Santé Et de la Recherche Médicale, France
Phase 2 Terminated
NCT05773274 2026-06-03
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07619950 2026-06-02
EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma
Yonsei University
Phase 2 Not yet recruiting
NCT05843253 2026-05-29
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT03008408 2026-05-22
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03114527 2026-05-22
Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT06955169 2026-05-22
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Suspended
NCT07340541 2026-05-20
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06428396 2026-05-18
LITESPARK-029
Merck Sharp & Dohme LLC
Phase 2 Recruiting